alexa Pharmaceutical Equivalent Study of Losartan Potassium Formulation available in Karachi, Pakistan | Open Access Journals
ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Pharmaceutical Equivalent Study of Losartan Potassium Formulation available in Karachi, Pakistan

Hameed A*, Naveed S, Abbas SS and Qamar F

Department of Pharmacy, Jinnah University for Women, 5C, Nazimabad, Karachi 74600, Pakistan

*Corresponding Author:
Hameed A
Faculty of Pharmacy, Jinnah University for Women
5C, Nazimabad, Karachi 74600, Pakistan
Tel: 922136620859
E-mail: [email protected]

Received date: October 11, 2016; Accepted date: November 08, 2016; Published date: November 21, 2016

Citation: Hameed A, Naveed S, Abbas SS, Qamar F (2016) Pharmaceutical Equivalent Study of Losartan Potassium Formulation available in Karachi, Pakistan. J Bioequiv Availab 8:283-284. doi: 10.4172/jbb.1000310

Copyright: © 2016 Hameed A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability


The purpose of this study is to check pharmaceutical equivalence of altered brands of Losartan Potassium tablets available in Karachi, Pakistan. Two different brands of Losartan Potassium tablets (50 mg) were investigated in the study. Five Quality Control (QC) parameters: Weight variation, thickness test, hardness, friability and disintegration tests were carried out as specified by BP/USP (British Pharmacopoeia and United State Pharmacopoeia). The result of study revealed that all above mentioned tests are in accordance with BP/USP. Both brands of Losartan Potassium tablets are Pharmaceutical Equivalent.


Losartan potassium; Weight variation; Hardness; Thickness; Friability; Disintegration


Losartan is a phenyl tetrazole deputize for imidazole compound and it is an Angiotensin Receptor Blocker II (ARB II) type I antagonist and it is used in the treatment of hypertension. Administration of Losartan results in a decrease Total Peripheral Resistance (TPR) and cardiac venous return [1]. Their pharmacologic effect is similar to that of the Angiotensin Converting Enzyme (ACE) inhibitors, since they also produce the arteriolar as well as venous dilation and blocks aldosterone secretion, thus lowers the blood pressure, salt content and water retention [2]. It is the prototypic ARB. Their pharmacologic effects are similar to the ACE inhibitors [3]. They decrease the nephrotoxicity of diabetes and makes attractive therapy in hypertensive diabetics [4]. Losartan is specific or selective type I Angiotensin II receptor (AT1) antagonist. They block receptor as a result decrease in blood pressure (Rennin-Angiotensin-Aldosterone System (RAAS)) [5]. Losartan inhibit the binding of angiotensin II to type I in tissue (kidney and adrenal glands) [6]. Losartan and its active metabolites E-3174 are more potent than losartan inhibition (angiotensin II to type I) and causes vasodilation (normally AT1 → vasoconstriction + aldosteron) decrease in sodium as well as water retention but increases excretion [6]. Protein binding of losartan is 99.7% (primarily albumin) and bioavailability is 25-35% [7]. The appearance of losartan potassium is white or may be off white crystalline powder where its melting point is between 263-265°C and it is freely soluble in water. Molecular mass of losartan potassium is 462.01 [8]. Its indications are: mild to severe hypertension, diabetic nephropathy reducing risk of stroke in people with heart disease [9]. Hypergranulosis and hyperkeratosis be developed during its treatment with losartan for arterial hypertension. Long term use of losartan potassium develops angioedema [2].

QC Parameter Testing

All QC parameters and physical appearance testing of altered brands of Losartan Potassium were carried out. Variation in weight was checked on A.N.D Electronic Balance FX-400. For which 20 tablets of each brand are selected randomly. The percentage weight variation from average tablet weights was calculated. In the weight variation test, the tablet should be within the limits of the percentage deviation allowed by BP. The degree of compaction of 10 tablet of each brand is assessed by measuring the thickness of tablets, using Vernier Caliper. Hardness of all the brands is checked on MH-1, Hardness Tester of Galvano Scientific. The hardness value of each tablet was evaluated and average value was calculated and compared. No. of tablets were calculated to perform friability test of each brand of ketotifen by subjecting to a uniform tumbling motion for specified period of time i.e., 25 rotation/min for 4 min in Fb-1004 Curio Company and the weight loss is determined. Disintegration test for all brands was done on Curro Model No Ds-0702. A 900 ml beaker was filled with distilled water and temperature was maintained at 37 ± 2°C. 6 tablets of each brand were selected randomly and placed into the basket rack assembly and connected to the disintegration apparatus. The disintegration time for each brand is compared with the Pharmacopoeia limit specified by BP.

Result and Discussion

The purpose of this research work was to compare and evaluate the quality standards of commercially available two brands of Losartan Potassium Tablet in Karachi, Pakistan. Losartan Potassium Tablets (50 mg) were evaluated comparatively for their physical parameters. Weight variation test of Losartan Potassium tablets proved statistically that all the tablets were in accordance to the BP/USP requirements as shown in the Tables 1-3. Thickness of all tablets of Losartan Potassium including standard deviation, average weight, upper & lower limits are in accordance with BP/USP as shown in the Tables 4 and 5. Hardness test of Losartan Potassium tablets were found within the BP/USP limits. Both the brands of Losartan Potassium passed the hardness test i.e., average hardness of both brands was found to be greater than 4 kg but less than 10 kg. Data of hardness test is given in Tables 6 and 7. Friability of both brands of Losartan Potassium tablets was less than 1%. Therefore, it is in compliance with the BP/USP standards. Its data is given in Table 8. Disintegration time of both the brands of naproxen is observed. Both the tablets disintegrated within 20 min which are in under the USP limits i.e., within 60 min for coated tablets. Data of disintegration test is shown in Table 9.

No. of Tablets Qsartan (g) Losartan (g)
1 155 175
2 145 167
3 153 171
4 152 176
5 149 174
6 151 164
7 150 173
8 157 177
9 160 172
10 150 172
11 150 176
12 150 173
13 155 170
14 151 167
15 153 172
16 153 175
17 143 168
18 149 176
19 152 172
20 150 168

Table 1: Weight of 20 tablets (randomly selected) of different brands.

Tablets Average (g) Standard deviation Upper limit Lower limit
(X+3S) (X-3S)
Qsartan 151 3.7 162.1 139.9
Losartan 171.9 3.61 182.73 161.07

Table 2: Statistical weight variations.

Tablets Result (g) BP/USP Specification Deviation from BP/USP Specification
Qsartan 151 Deviation should be ±7.5% Within specified limit
Losartan 171.9 Deviation should be ±7.5%

Table 3: Weight variation test.

Number of sample Qsartan Losartan
1 6 9
2 9 6
3  9 8
4 6 9
5 7 9
6 9 9
7 9 9
8 8  8
9 9 6
10 9 7

Table 4: Thickness of 10 tablets (mm)

No. of tablets Average thickness (mm) Standard deviation Upper limit Lower limit
(X+3S) (X-3S)
Qsartan 8.1 1.28 11.94 4.26
Losartan 8 1.24 11.72 4.28

Table 5: Statistical thickness

Number of sample Qsartan (kg) Losartan (kg)
1 6.66 7.27
2 5.74 7.16
3 6.40 7.05
4 7.30 6.88
5 5.64 6.65
6 5.97 6.46
7 5.55 6.36
8 6.23 6.40
9 6.80 6.23
10 6.21 6.14

Table 6: Hardness of 10 tablets from the optimized formulation.

No. of tablets Average hardness (kg) Standard deviation Upper limit (X+3S) Lower limit (X-3S)
Qsartan 6.25 0.55 7.9 4.6
Losartan 6.66 0.40 7.86 5.46

Table 7: Statistical hardness calculation.

Tablets Friability (%) BP/USP specification Deviation from BP/USP specification
Qsartan 0.65% Not more than 1% Within the specified limit
Losartan 0.035% Within the specified limit

Table 8: Friability test.

Tablet Disintegration time (min) Limits Deviation from USP
Qsartan 10.25 Not more than 60 min for coated tablets PASS
Losartan 20 PASS

Table 9: Disintegration test.


Both the two brands of Losartan Potassium are pharmaceutical equivalents. No Difference was detected in weight variation testing, thickness testing, hardness testing, friability testing and disintegration testing of tablets.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8444
  • [From(publication date):
    November-2016 - Aug 23, 2017]
  • Breakdown by view type
  • HTML page views : 8375
  • PDF downloads :69

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version